Vitamin E, specifically in the form of tocopheryl succinate, has some scientific evidence supporting its use in the management of certain types of migraines, particularly menstrual migraine (also called catamenial migraine). A few small, randomized controlled trials have evaluated the efficacy of Vitamin E supplementation in reducing migraine frequency and severity in women whose migraines are closely related to their menstrual cycle. The proposed mechanism involves Vitamin E's antioxidant properties and its ability to stabilize cell membranes and modulate prostaglandin synthesis, which may be relevant in the pathophysiology of menstrual migraines.

The most frequently cited study is a double-blind, placebo-controlled trial published in 1998, which showed that 400 IU of Vitamin E daily reduced migraine frequency, severity, and associated symptoms in women with menstrual migraine. However, the sample size was small, and the studies have not been widely replicated. There is little evidence for Vitamin E's benefit in migraine outside of this specific subgroup. Guidelines generally do not include Vitamin E as a first-line migraine therapy, and evidence for its use in non-menstrual migraine is lacking.

In summary, while there is modest scientific support for Vitamin E (tocopheryl succinate) in the context of menstrual migraine, the overall evidence base is limited in size and scope, and routine use for all migraine types is not broadly endorsed.